Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)" to "Chronic lymphocytic leukemia (CLL/SLL)") |
m |
||
| Line 11: | Line 11: | ||
*[[Hairy cell leukemia]] | *[[Hairy cell leukemia]] | ||
*[[Hypereosinophilic syndrome]] | *[[Hypereosinophilic syndrome]] | ||
| + | *[[Langerhans cell histiocytosis]] | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
| Line 24: | Line 25: | ||
==Also known as== | ==Also known as== | ||
| − | 2-chlorodeoxyadenosine, 2-CdA, Litak, Movectro | + | *'''Generic names:''' 2-chlorodeoxyadenosine, 2-CdA |
| + | *'''Brand names:''' Leustatin, Litak, Movectro | ||
==References== | ==References== | ||
| Line 30: | Line 32: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
| Line 42: | Line 43: | ||
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
[[Category:Hypereosinophilic syndrome medications]] | [[Category:Hypereosinophilic syndrome medications]] | ||
| + | [[Category:Langerhans cell histiocytosis medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
Revision as of 19:43, 6 November 2017
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV
Extravasation: irritant or neutral, depending on reference
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia (CLL/SLL)
- Hairy cell leukemia
- Hypereosinophilic syndrome
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Systemic mastocytosis
- Waldenström macroglobulinemia
Patient drug information
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/26/1993: Initial FDA approval
Also known as
- Generic names: 2-chlorodeoxyadenosine, 2-CdA
- Brand names: Leustatin, Litak, Movectro
References
Categories:
- Drug index
- Intravenous medications
- Irritant chemotherapy
- Neutral chemotherapy
- Antimetabolites
- Purine analogues
- Acute myeloid leukemia medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Hairy cell leukemia medications
- Hypereosinophilic syndrome medications
- Langerhans cell histiocytosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Systemic mastocytosis medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1993